赞比亚HBV/HIV合并感染成人接受含替诺福韦抗逆转录病毒治疗的长期乙型肝炎与肝脏结局
在赞比亚开展的前瞻性队列纳入289例启动含替诺福韦抗逆转录病毒治疗的HBV/HIV合并感染成人,中位随访5.91年。13.6%出现HBV病毒学未抑制,ALT升高与HBV病毒学未抑制相关,纤维化/肝硬化消退常见、无肝硬化进展及肝细胞癌发生;HBsAg清除率2年9.4%、5年15.4%。
要点
- 中位随访5.91年,13.6%出现HBV病毒学未抑制,与晚期HIV疾病相关。
- ALT升高与HBV病毒学未抑制相关;纤维化/肝硬化消退常见,无肝硬化进展及肝细胞癌。
- HBsAg清除率2年9.4%、5年15.4%,基线HBV复制标志物低者更高。
核心结论
- 在赞比亚含替诺福韦抗逆转录病毒治疗HBV/HIV合并感染中观察到令人安心的长期肝脏结局。
- 治疗期间HBsAg清除率高于预期,提示需将HIV感染者纳入HBV治愈研究。
研究设计与样本
- 前瞻性队列研究,纳入289例启动抗逆转录病毒治疗的HIV且HBsAg阳性成人。
- 评估含替诺福韦治疗下的HBV病毒载量未抑制、ALT升高、血清学终点、基于弹性成像的肝纤维化进展及肝细胞癌发生率。
- 描述了一个基线低HBV病毒载量且无/极少纤维化、按现行国际指南在无HIV感染时不会接受治疗的亚组。
主要发现
- 启动抗逆转录病毒治疗时中位年龄34岁,40.1%为女性,中位CD4计数191 cells/mm3,44.2%为HBeAg阳性,28.4%有肝纤维化/肝硬化。
- 中位5.91年抗逆转录病毒治疗期间,13.6%出现HBV病毒学未抑制,与晚期HIV疾病相关。
- 抗逆转录病毒治疗期间ALT升高与HBV病毒载量未抑制相关。
- 纤维化与肝硬化消退常见,无进展至肝硬化,未发现肝细胞癌病例。
- HBsAg清除率2年9.4%、5年15.4%,基线HBV复制标志物低的患者中更高。
关键数值与推荐
- HBsAg清除率:2年9.4%,5年15.4%。
- HBV病毒学未抑制:13.6%。
- 基线肝纤维化/肝硬化:28.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term outcomes of tenofovir-containing antiretroviral therapy (ART) for hepatitis B virus (HBV)/human immunodeficiency virus (HIV) coinfection were evaluated in Zambia. METHODS: A prospective cohort of adults with HIV and hepatitis B surface antigen (HBsAg)-positivity was enrolled at ART initiation. On tenofovir-containing ART, we ascertained HBV viral load (VL) non-suppression, alanine aminotransferase (ALT) elevation, serologic end-points, progression of liver fibrosis based on elastography, and hepatocellular carcinoma (HCC) incidence. We also described a subgroup (low HBV VL and no/minimal fibrosis at baseline) that, under current international guidelines, would not have been treated in the absence of their HIV infection. RESULTS: Among 289 participants at ART start, median age was 34 years, 40.1% were women, median CD4 count was 191 cells/mm3, 44.2% were hepatitis B e antigen-positive, and 28.4% had liver fibrosis/cirrhosis. Over median 5.91 years of ART, 13.6% developed HBV viral non-suppression, which was associated with advanced HIV disease. ALT elevation on ART was linked with HBV VL non-suppression. Regression of fibrosis and cirrhosis were common, progression to cirrhosis was absent, and no cases of HCC were ascertained. HBsAg seroclearance was 9.4% at 2 and 15.4% at 5 years, with higher rates among patients with low baseline HBV replication markers. CONCLUSIONS: Reassuring long-term liver outcomes were ascertained during tenofovir-based ART for HBV/HIV coinfection in Zambia. Higher than expected HBsAg seroclearance during ART underscores the need to include people with HIV in HBV cure research.
引用
- Vinikoor MJ, Hamusonde K, Muula G, et al. Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia. Clin Infect Dis. 2024. PMID: 37997691. doi:10.1093/cid/ciad654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。